ALDX — Aldeyra Therapeutics Share News
0.000.00%
Last trade - 00:00Newscasts - Trading at Noon: US consumer confidence rises for the first time in four months
Aldeyra falls after US FDA declines to approve eye disease drug
U.S. RESEARCH ROUNDUP-Amkor Technology, Boeing, Nogin
Aldeyra falls as FDA declines to approve its eye disease drug
What to Watch in the Week Ahead and on Monday, November 20
U.S. RESEARCH ROUNDUP-Appian Corp, Eversource Energy, Victoria'S Secret & Co
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co., Costco Wholesale, Idexx Laboratories
U.S. STOCKS ON THE MOVE-Kraft Heinz, Humana, Estee Lauder
U.S. STOCKS ON THE MOVE-Martin Marietta, Boeing, Netflix
Aldeyra rises on agreement with AbbVie for eye drug
Brief: Aldeyra Therapeutics Enters Into Exclusive Option Agreement With AbbVie For License To Develop And Commercialize Reproxalap
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
U.S. STOCKS ON THE MOVE-Moderna, Aldeyra Therapeutics, Colgate-Palmolive
Aldeyra plummets, says FDA may decline to approve its eye disease drug
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork
Brief: Knoll Capital Management Llc Reports 6.1% Passive Stake In Aldeyra Therapeutics As Of Sept 28
Aldeyra Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Announces Improvement From Baseline In Retinal Function In Phase 2 Clinical Trial Of ADX‑2191